S&P 500   4,526.01 (-1.12%)
DOW   34,487.88 (-0.44%)
QQQ   382.95 (-1.79%)
AAPL   162.44 (-0.81%)
MSFT   323.10 (-1.94%)
FB   305.04 (-1.72%)
GOOGL   2,824.20 (-1.23%)
AMZN   3,395.56 (-1.22%)
TSLA   1,023.75 (-5.61%)
NVDA   306.15 (-4.70%)
BABA   112.16 (-8.07%)
NIO   32.75 (-9.53%)
CGC   10.11 (-2.41%)
AMD   143.05 (-5.06%)
GE   93.06 (-2.28%)
MU   82.50 (-0.46%)
T   23.37 (+1.39%)
F   19.41 (-2.32%)
DIS   146.05 (-0.78%)
PFE   53.75 (+1.34%)
AMC   28.22 (-6.80%)
ACB   5.93 (-3.42%)
BA   197.13 (-2.59%)
S&P 500   4,526.01 (-1.12%)
DOW   34,487.88 (-0.44%)
QQQ   382.95 (-1.79%)
AAPL   162.44 (-0.81%)
MSFT   323.10 (-1.94%)
FB   305.04 (-1.72%)
GOOGL   2,824.20 (-1.23%)
AMZN   3,395.56 (-1.22%)
TSLA   1,023.75 (-5.61%)
NVDA   306.15 (-4.70%)
BABA   112.16 (-8.07%)
NIO   32.75 (-9.53%)
CGC   10.11 (-2.41%)
AMD   143.05 (-5.06%)
GE   93.06 (-2.28%)
MU   82.50 (-0.46%)
T   23.37 (+1.39%)
F   19.41 (-2.32%)
DIS   146.05 (-0.78%)
PFE   53.75 (+1.34%)
AMC   28.22 (-6.80%)
ACB   5.93 (-3.42%)
BA   197.13 (-2.59%)
S&P 500   4,526.01 (-1.12%)
DOW   34,487.88 (-0.44%)
QQQ   382.95 (-1.79%)
AAPL   162.44 (-0.81%)
MSFT   323.10 (-1.94%)
FB   305.04 (-1.72%)
GOOGL   2,824.20 (-1.23%)
AMZN   3,395.56 (-1.22%)
TSLA   1,023.75 (-5.61%)
NVDA   306.15 (-4.70%)
BABA   112.16 (-8.07%)
NIO   32.75 (-9.53%)
CGC   10.11 (-2.41%)
AMD   143.05 (-5.06%)
GE   93.06 (-2.28%)
MU   82.50 (-0.46%)
T   23.37 (+1.39%)
F   19.41 (-2.32%)
DIS   146.05 (-0.78%)
PFE   53.75 (+1.34%)
AMC   28.22 (-6.80%)
ACB   5.93 (-3.42%)
BA   197.13 (-2.59%)
S&P 500   4,526.01 (-1.12%)
DOW   34,487.88 (-0.44%)
QQQ   382.95 (-1.79%)
AAPL   162.44 (-0.81%)
MSFT   323.10 (-1.94%)
FB   305.04 (-1.72%)
GOOGL   2,824.20 (-1.23%)
AMZN   3,395.56 (-1.22%)
TSLA   1,023.75 (-5.61%)
NVDA   306.15 (-4.70%)
BABA   112.16 (-8.07%)
NIO   32.75 (-9.53%)
CGC   10.11 (-2.41%)
AMD   143.05 (-5.06%)
GE   93.06 (-2.28%)
MU   82.50 (-0.46%)
T   23.37 (+1.39%)
F   19.41 (-2.32%)
DIS   146.05 (-0.78%)
PFE   53.75 (+1.34%)
AMC   28.22 (-6.80%)
ACB   5.93 (-3.42%)
BA   197.13 (-2.59%)
NASDAQ:SCYX

SCYNEXIS Stock Forecast, Price & News

$6.28
-0.39 (-5.85%)
(As of 12/3/2021 11:22 AM ET)
Add
Compare
Today's Range
$6.16
$6.42
50-Day Range
$4.94
$7.69
52-Week Range
$4.90
$10.25
Volume
2,890 shs
Average Volume
480,790 shs
Market Capitalization
$150.41 million
P/E Ratio
N/A
Dividend Yield
N/A
Beta
2.13
30 days | 90 days | 365 days | Advanced Chart
Receive SCYX News and Ratings via Email

Sign-up to receive the latest news and ratings for SCYNEXIS and its competitors with MarketBeat's FREE daily newsletter.


SCYNEXIS logo

About SCYNEXIS

SCYNEXIS, Inc. is a biotechnology company, which engages in the development of novel oral and intravenous triterpenoid antifungal for the treatment of several serious fungal infections, including vulvovaginal candidiasis, invasive aspergillosis, invasive candidiasis, and refractory invasive fungal infections. The company was founded by Scot Kevin Huber, Terry Eugene Marquardt, Pierre Bernard Jacques Monnet, Russell J. Outcalt, and Yves Joseph Ribeill on November 4, 1999 and is headquartered in Jersey City, NJ.

Headlines

Is SCYNEXIS (NASDAQ:SCYX) Using Debt Sensibly?
December 1, 2021 |  finance.yahoo.com
See More Headlines

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:SCYX
Employees
38
Year Founded
N/A

Sales & Book Value

Annual Sales
$120 thousand
Book Value
$1.62 per share

Profitability

Net Income
$-55.19 million
Pretax Margin
-393.33%

Debt

Price-To-Earnings

Miscellaneous

Free Float
22,405,000
Market Cap
$150.41 million
Optionable
Optionable

Company Calendar

Last Earnings
11/10/2021
Today
12/03/2021
Fiscal Year End
12/31/2021
Next Earnings (Estimated)
4/04/2022

MarketRank

Overall MarketRank

1.95 out of 5 stars

Medical Sector

685th out of 1,391 stocks

Pharmaceutical Preparations Industry

320th out of 669 stocks

Analyst Opinion: 3.5Community Rank: 4.8Dividend Strength: 0.0Insider Behavior: 0.8Valuation: 0.6 5 -4 -3 -2 -1 -












SCYNEXIS (NASDAQ:SCYX) Frequently Asked Questions

Is SCYNEXIS a buy right now?

6 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for SCYNEXIS in the last twelve months. There are currently 6 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" SCYNEXIS stock.
View analyst ratings for SCYNEXIS
or view top-rated stocks.

How has SCYNEXIS's stock been impacted by COVID-19 (Coronavirus)?

SCYNEXIS's stock was trading at $7.8020 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, SCYX stock has decreased by 19.5% and is now trading at $6.28.
View which stocks have been most impacted by COVID-19
.

When is SCYNEXIS's next earnings date?

SCYNEXIS is scheduled to release its next quarterly earnings announcement on Monday, April 4th 2022.
View our earnings forecast for SCYNEXIS
.

How were SCYNEXIS's earnings last quarter?

SCYNEXIS, Inc. (NASDAQ:SCYX) announced its quarterly earnings data on Wednesday, November, 10th. The company reported ($0.06) EPS for the quarter, beating analysts' consensus estimates of ($0.79) by $0.73. During the same period last year, the firm posted ($0.28) EPS.
View SCYNEXIS's earnings history
.

When did SCYNEXIS's stock split? How did SCYNEXIS's stock split work?

SCYNEXIS shares reverse split on the morning of Friday, July 17th 2020. The 1-10 reverse split was announced on Thursday, July 16th 2020. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, July 16th 2020. An investor that had 100 shares of SCYNEXIS stock prior to the reverse split would have 10 shares after the split.

What price target have analysts set for SCYX?

6 Wall Street analysts have issued twelve-month target prices for SCYNEXIS's shares. Their forecasts range from $20.00 to $35.00. On average, they anticipate SCYNEXIS's share price to reach $26.40 in the next twelve months. This suggests a possible upside of 320.4% from the stock's current price.
View analysts' price targets for SCYNEXIS
or view top-rated stocks among Wall Street analysts.

Who are SCYNEXIS's key executives?

SCYNEXIS's management team includes the following people:
  • Marco Taglietti, President, Chief Executive Officer & Director
  • Eric Francois, Chief Financial Officer
  • David Angulo Gonzalez, Chief Medical Officer
  • Rajeshwar Motheram, SVP-Pharmaceutical Development & Supply Chain
  • Nkechi Azie, VP-Clinical Development & Medical Affairs

What other stocks do shareholders of SCYNEXIS own?

What is SCYNEXIS's stock symbol?

SCYNEXIS trades on the NASDAQ under the ticker symbol "SCYX."

Who are SCYNEXIS's major shareholders?

SCYNEXIS's stock is owned by many different institutional and retail investors. Top institutional investors include Caxton Corp (6.74%), AIGH Capital Management LLC (1.48%), BlackRock Inc. (1.40%), Two Sigma Advisers LP (1.03%), Geode Capital Management LLC (0.69%) and Telemetry Investments L.L.C. (0.61%). Company insiders that own SCYNEXIS stock include Brian Philippe Tinmouth, Eric Francois, Marco Taglietti, Perceptive Advisors Llc and Scott Sukenick.
View institutional ownership trends for SCYNEXIS
.

Which major investors are selling SCYNEXIS stock?

SCYX stock was sold by a variety of institutional investors in the last quarter, including AIGH Capital Management LLC, Two Sigma Investments LP, Two Sigma Advisers LP, Citadel Advisors LLC, GSA Capital Partners LLP, Geode Capital Management LLC, and BlackRock Inc..
View insider buying and selling activity for SCYNEXIS
or view top insider-selling stocks.

Which major investors are buying SCYNEXIS stock?

SCYX stock was purchased by a variety of institutional investors in the last quarter, including Brandywine Global Investment Management LLC, Caxton Corp, Altium Capital Management LP, Bank of New York Mellon Corp, Morgan Stanley, Private Advisor Group LLC, Telemetry Investments L.L.C., and Stonepine Capital Management LLC. Company insiders that have bought SCYNEXIS stock in the last two years include Brian Philippe Tinmouth, Eric Francois, Marco Taglietti, and Scott Sukenick.
View insider buying and selling activity for SCYNEXIS
or or view top insider-buying stocks.

How do I buy shares of SCYNEXIS?

Shares of SCYX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is SCYNEXIS's stock price today?

One share of SCYX stock can currently be purchased for approximately $6.28.

How much money does SCYNEXIS make?

SCYNEXIS has a market capitalization of $150.41 million and generates $120 thousand in revenue each year. The company earns $-55.19 million in net income (profit) each year or ($4.43) on an earnings per share basis.

How many employees does SCYNEXIS have?

SCYNEXIS employs 38 workers across the globe.

What is SCYNEXIS's official website?

The official website for SCYNEXIS is www.scynexis.com.

Where are SCYNEXIS's headquarters?

How can I contact SCYNEXIS?

SCYNEXIS's mailing address is 1 EVERTRUST PLAZA 13TH FLOOR, JERSEY CITY NJ, 07302. The company can be reached via phone at (201) 884-5485, via email at [email protected], or via fax at 201-884-5490.


This page was last updated on 12/3/2021 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.